A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

Inclusion Criteria:

- Primary study: Male or female participants between the ages of 12 and 50 years,
inclusive, at randomization.

- Booster study: Male or female participants between the ages of 18 and 50 years,
inclusive, at rerandomization.

- Participants who are willing and able to comply with all scheduled visits, treatment
plan, laboratory tests, lifestyle considerations, and other study procedures.

- Healthy participants who are determined by medical history, physical examination (if
required), and clinical judgment of the investigator to be eligible for inclusion in
the study.

- Capable of giving personal signed informed consent/have parent(s)/legal guardian
capable of giving signed informed consent.

Exclusion Criteria:

- Other medical or psychiatric condition including recent (within the past year) or
active suicidal ideation/behavior or laboratory abnormality that may increase the risk
of study participation or, in the investigator's judgment, make the participant
inappropriate for the study.

- Known infection with HIV, HCV, or HBV.

- History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the study intervention.

- Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result
was not available) or microbiological (based on COVID-19 symptoms/signs and a positive
SARS-CoV-2 NAAT result) diagnosis of COVID 19.

. Immunocompromised individuals with known or suspected immunodeficiency, as
determined by history and/or laboratory/physical examination.

- Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.

- Women who are pregnant or breastfeeding.

- Primary study: Previous vaccination with any coronavirus vaccine.

- Booster study: Previous vaccination with any coronavirus vaccine outside of this
study.

- Receipt of medications intended to prevent COVID-19.

- Individuals who receive treatment with radiotherapy or immunosuppressive therapy,
including cytotoxic agents or systemic corticosteroids, eg, for cancer or an
autoimmune disease, or planned receipt throughout the study.

- Receipt of blood/plasma products or immunoglobulin, from 60 days before study
intervention administration or planned receipt throughout the study.

- Participation in other studies involving study intervention within 28 days prior to
study entry and/or during study participation.

- Previous participation in other studies involving study intervention containing lipid
nanoparticles.

- Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct
of the study, site staff otherwise supervised by the investigator, and their
respective family members.

Additional Exclusion Criteria for the Booster study:

- Current febrile illness (body temperature ≥100.4°F [≥38.0°C]) or other acute illness
within 48 hours before study intervention administration.

- Receipt of any seasonal or pandemic influenza vaccine within 14 days, or any other
nonstudy vaccine within 28 days, before or after study intervention administration.

- Receipt of short-term (<14 days) systemic corticosteroids. Inhaled/nebulized,
intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.